{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Disease", "query": { "condition": "Colorectal Disease" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 3283, "total_pages": 329, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Disease&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T00:56:46.730Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2 Mutation-Related Tumors", "HER2-positive Metastatic Breast Cancer", "KRAS Mutant Metastatic Colorectal Cancer", "Metastatic Lung Cancer", "Metastatic Colorectal Cancer", "Advanced Lung Cancer", "HR-positive, HER2-negative Advanced Breast Cancer", "HER2-positive Advanced Breast Cancer" ], "interventions": [ { "name": "BBO-10203", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 392, "start_date": "2024-10-29", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625775" }, { "nct_id": "NCT03823144", "title": "Intravital Microscopy in Human Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Solid Tumor, Adult", "Clinical Stage IV Gastric Cancer AJCC v8", "Malignant Solid Neoplasm", "Metastatic Colorectal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Primary Malignant Brain Neoplasm", "Metastatic Sarcoma", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Resectable Colorectal Carcinoma", "Resectable Liver and Intrahepatic Bile Duct Carcinoma", "Resectable Pancreatic Carcinoma", "Resectable Sarcoma", "Stage IV Colorectal Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Malignant Brain Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Pancreatic Carcinoma", "Resectable Brain Neoplasm", "Resectable Breast Carcinoma", "Resectable Gastric Carcinoma", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Diagnostic Microscopy", "type": "DEVICE" }, { "name": "Fluorescein Sodium Injection", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-02-28", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03823144" }, { "nct_id": "NCT02192034", "title": "Optimizing Navigation to Successful Colorectal Cancer Screening", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer Screening" ], "interventions": [ { "name": "Navigation", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 156, "start_date": "2013-03", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192034" }, { "nct_id": "NCT04294264", "title": "TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Carcinoma", "Recurrent Colon Carcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colon Cancer AJCC v7", "Stage IVA Colon Cancer AJCC v7", "Stage IVB Colon Cancer AJCC v7" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2019-02-12", "completion_date": "2026-03-27", "has_results": false, "last_update_posted_date": "2024-11-18", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 6, "location_summary": "Elizabeth, New Jersey • Lakewood, New Jersey • Livingston, New Jersey + 3 more", "locations": [ { "city": "Elizabeth", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04294264" }, { "nct_id": "NCT02289053", "title": "Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Colon Polyps", "Adenomatous Polyp of Colon" ], "interventions": [], "intervention_types": [], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "40 Years to 49 Years" }, "enrollment_count": 1623, "start_date": "2006-04-01", "completion_date": "2014-06-30", "has_results": false, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 6, "location_summary": "Bethesda, Maryland • Ann Arbor, Michigan • Detroit, Michigan + 2 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Ypsilanti", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289053" }, { "nct_id": "NCT03597581", "title": "A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer", "Gastrointestinal Neoplasms", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Carcinoma", "Gastric Cancer", "Gastric Neoplasm", "KRAS Mutation-Related Tumors", "CRC", "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "ompenaclid", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inspirna, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2018-06-05", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 17, "location_summary": "Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03597581" }, { "nct_id": "NCT05520099", "title": "Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immunotherapy", "Cancer", "Bladder Cancer", "Urothelial Carcinoma Bladder", "Kidney Cancer", "Clear Cell Renal Cell Cancer (ccRCC)", "Colorectal Cancer", "MSI-H Colorectal Cancer", "DMMR Colorectal Cancer", "Head and Neck Cancer (H&N)", "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)", "Liver Cancer", "Hepatocellular Carcinoma (HCC)", "Lung Cancer (NSCLC)", "NSCLC (Non-small Cell Lung Cancer)", "Skin Cancer", "Cutaneous Melanoma", "Endometrial Cancer", "Solid Tumor Cancer" ], "interventions": [ { "name": "Core Needle Biopsy, Forceps Biopsy, Punch Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Elephas", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416, "start_date": "2023-06-26", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Salinas", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05520099" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT05524428", "title": "Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colo-rectal Cancer" ], "interventions": [ { "name": "Implementation Science Strategy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-03-24", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Brockton, Massachusetts • East Boston, Massachusetts + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Brockton", "state": "Massachusetts" }, { "city": "East Boston", "state": "Massachusetts" }, { "city": "Hyannis", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05524428" }, { "nct_id": "NCT02963831", "title": "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Ovarian Cancer", "Appendiceal Cancer" ], "interventions": [ { "name": "ONCOS-102", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2017-09-07", "completion_date": "2022-06-25", "has_results": true, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-07-24T00:56:46.730Z", "location_count": 6, "location_summary": "San Diego, California • Miami, Florida • Buffalo, New York + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02963831" } ] }